On March 30, 2021, Design Therapeutics, Inc. (Design), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, announced the closing of its previously announced initial public offering of 13,800,000 shares of its common stock, which includes 1,800,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $20 per share. Including the option exercise, the aggregate gross proceeds to Design from the offering were approximately $276 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market on March 26, 2021, under the ticker symbol “DSGN.”

The Wilson Sonsini Goodrich & Rosati team that advised Design Therapeutics on patent matters related to the IPO includes Michael Hostetler, Uale Taotafa, and Katrina Otrubova.

For more information, please see Design Therapeutics' press release.